Skip to main content

Table 1 Selected characteristics of enrolled subjects in this study

From: Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure

 

ATV/r (n = 21)

LPV/r (n = 20)

P value

Sex (M/F)

21/0

20/0

 

Age: median, range (years)

33.5, 21-45

35, 22-57

0.53

CD4 cell count at baseline: median, range (per μgL)

132, 25-367

121, 18-340

0.37

Plasma HIV RNA at baseline: median, range (copies/mL)

35200, 7500-232000

28900, 3500-356000

0.42

CD4 cell count at virological failure: median, range (per μgL)

195, 37-468

202, 65-520

0.56

Plasma HIV RNA at virological failure: median, range (copies/mL)

26500, 1500-87300

22500, 2200-67200

0.37

History of AIDS: no. (%)

14 (67)

15 (75)

0.808

Experienced to NNRTI: no. (%)

12 (57)

13 (65)

0.845

Duration of PI exposure: median, range (months)

13.2, 4.8-18

11.3, 3.5-17

0.32